Online Adaptive Radiotherapy for Cervical Cancer
For patients and families
In plain language
An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.
- What is being studied
- The protocol lists: online adaptive radiotherapy.
- Who it may be relevant to
- Registry conditions: Cervical Cancer. Basic parameters: 18 years — 80 years · Female.
- What needs checking
- Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
- Where it takes place
- China
- Next step
- Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Unsure about the terms? Read our patient guide →
Official title
Online Adaptive Radiotherapy (oART) in Radical Radiotherapy for Cervical Cancer - A Multi-center Randomized Controlled Study
Overview
This study aims to evaluate the clinical efficacy and safety of online adaptive radiotherapy for cervical cancer patients received radical radiotherapy. By comparing with image-guided radiotherapy, the study explores the potential advantages of online adaptive radiotherapy in reducing treatment toxicity and improving local control.
Interventions
- Radiation online adaptive radiotherapy
Patients in ART group received daily online adaptive radiotherapy with a prescription dose of 50.4Gy/28f.
Primary outcome measures
- Acute non-hematological toxicity [Time frame: From the start of treatment until 3 months later]
Secondary outcome measures (1)
- treatment response [Time frame: 3 months after completion of treatment]
Eligibility criteria
Inclusion criteria
- 18-80 years old;
- Pathologically confirmed diagnosis of cervical cancer and pathological type of cervical squamous carcinoma;
- 2018 FIGO Stage Ib3, II, IIIB and IIIC1
- Proposed radical pelvic radiotherapy + concurrent sensitizing chemotherapy (platinum-based (cisplatin 30-40mg/m2 or carboplatin alone), starting concurrently in the first week, ≥5 courses)
- ECOG score 0-2
- Life expectancy greater than 6 months
- Ability to remain lying down for more than 30 minutes
- Patients were fully voluntary and autonomous and co-operated in signing the study informed consent form
- Complete blood count and basal metabolic indexes within 14 days before enrolment must meet the following requirements: NEUT ≥ 1.5\*109/L, HGB ≥ 60g/L, platelets ≥ 100×109/, blood creatinine \<1.5 mg/dL. AST and ALT are within 2 times the upper limit of normal
- Must complete baseline assessments and investigations required before treatment before enrolment
- be eligible for regular follow-up
Exclusion criteria
- Have received radiotherapy or chemotherapy in the past
- Have undergone radical surgery for cervical cancer
- Have a previous history of malignant tumor
- Pregnant or lactating women
- Presence of other serious co-morbidities such as poorly controlled cardiovascular, urinary, digestive, respiratory, hematological and central nervous system diseases.
Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.
Healthy volunteers: No
Study design
- Allocation
- Randomized
- Model
- Parallel assignment
- Masking
- Single blind
- Primary purpose
- Treatment
Study locations
China · 1 center
- Peking union medical college hospital — Beijing
Identifiers
NCT: NCT06562166 · ART_cervical cancer